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Summary
Endothelium-derived nitric oxide (NO) causes vasodilatation by activating soluble guanylate cyclase,
and glomerular mesangial cells respond to NO with elevations of intracellular guanosine 3,5'-
cyclic monophosphate (cGMP). We explored whether mesangial cells can be stimulated to produce
NO and whether NO modulates mesangial cell function in an autocrine or paracrine fashion.
Tumor necrosis factor alpha (TNF-a) raised mesangial cell cGMP levels in a time- and concentration-
dependent manner (threshold dose 1 ng/ml, ICso 13.8 ng/ml, maximal response 100 ng/ml).
TNF-a-induced increases in mesangial cGMP content were evident at 8 h and maximal at 18-
24 h. The TNF-a-induced stimulation of mesangial cell cGMP production was abrogated by
actinomycin D or cyloheximide suggesting dependence on new RNA or protein synthesis.
Hemoglobin and methylene blue, both known to inhibit NO action, dramatically reduced TNF-
ac-induced mesangial cell cGMP production. Superoxide dismutase, known to potentiate NO
action, augmented the TNF-a-induced effect. Ng-monomethyl-L-arginine (L-NMMA) decreased
cGMP levels in TNF-a-treated, but not vehicle-treated mesangial cells in a concentration-dependent
manner (ICso 53 PM). L-arginine had no effect on cGMP levels in control or TNF-a-treated
mesangial cells but reversed L-NMMA-induced inhibition. Interleukin 1/3 and lipopolysaccharide
(LPS), but not interferon y, also increased mesangial cell cGMP content. Transforming growth
factor (31 blunted the mesangial cell response to TNF-a. TNF-a-induced L-arginine-dependent
increases in cGMP were also evident in bovine renal artery vascular smooth muscle cells, COS-1
cells, and 1502 human fibroblasts.
These findings suggest that TNF-a induces expression in mesangial cell ofan enzyme(s) involved
in the formation of L-arginine-derived NO. Moreover, the data indicate that NO acts in an autocrine
and paracrine fashion to activate mesangial cell soluble guanylate cyclase. Cytokine-induced formation
of NO in mesangial and vascular smooth muscle cells may be implicated in the pathogenesis
of septic shock.
T
umor necrosis factor a (TNF-a), also known as cachectin,
has been implicated as a primary mediator in the patho-
genesis of septic shock, LPS-induced fever, and wasting as-
sociated with chronic disease or disseminated malignancy(1-4).
Animals infused with TNF-a developed changes in systemic
hemodynamics, including profound reductions in peripheral
vascular resistance and organ failure characteristic of gram-
negative septicemia or LPS administration (4). Furthermore,
animals passively immunized against endogenous TNF-a did
not develop septic shock when challenged with a standard
LDtoo dose of live Escherichia coli and failed to develop a sys-
temic hemodynamic response to LPS administration (5, 6).
Such observations suggested that TNF-a mediates many of
the pathophysiologic sequelae of gram-negative sepsis. How-
ever, little is known about the mechanisms involved in
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TNF-a-induced hemodynamic changes. Pathways involving
stimulation of phospholipase A2 (7-9), GTPase activity (10),
and ADP-ribosylation (11) in the cellular action of TNF-a
have been reported.
Synthesis of nitric oxide (NO)1 is a newly discovered bio-
chemical process in mammals. NO, derived from the guanido
nitrogens ofL-arginine, has been characterized as endothelium-
1 Abbreviations used in this paper: cGMP, 5'-cyclic monophosphate; EDRF,
endothelium-derived relaxing factor; GMC, glomerular mesangial cells;
LNMMA, NB-monomethyl-o-arginine; NO, nitric oxide; SCS, supple-
mented FCS; SOD, superoxide dismutase; VSMC, vascular smooth muscle
cells.
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endothelium (12-15) and amediator of macrophage-induced
cytotoxicity (16, 17). NO generation is constitutively expressed
in endothelial cells, yet in macrophages, NO generation re-
quires treatment of cells with cytokines, such as IFN-,y or
LPS. In the renal glomerulus, tone of the mesangial cell, a
specialized vascular smooth muscle cell, regulates glomerular
filtration by altering glomerular capillarysurface area. It was
therefore of interest to determine whether cytokine-activated
mesangial cells, like activatedmacrophages, express NO syn-
thase. Giventhat glomerular mesangialcells (GMC)respond
to endothelial-derived NO with elevations of intracellular
guanosine 3', 5'-cyclic monophosphate (cGMP) (18, 19), we
explored whetherGMCproduceNO andwhether NO modu-
lates GMC function in an autocrine or paracrine fashion.
Materials and Methods
Materials.
￿
Cell culture media and balanced salt solutions were
purchasedfrom Gibco Laboratories, Grand Island, NY; low endo-
toxindefined supplemented bovine calf serum (SCS) from HyClone
Laboratories, Logan, UT, cGMP RIA kits from Biomedial Tech-
nologies, Stoughton, MA; cell culture plates from Costar, Cam-
bridge, MA; Millicellculture inserts from Millipore Products Di-
vision, Bedford, MA; Ng-monomethyl-L-arginine (L-NMMA)
from Calbiochem-Behring, San Diego, CA; glasscoverslips from
Bellco Biotechnology, Vineland, NJ; human recombinant TNF-a
(rHuTNF-a, specific activity 5.0 x 10' U/mg) and rHuIFN-'f
(specific activity, 3.4 x 10'U/mg) were gifts of Genentech (South
San Francisco, CA); rHuIIri0 (specific activity, 3 x 10' U/mg)
was a gift of The Upjohn Co., Kalamazoo, MI; porcine platelet-
derived TGF-01 from R & D Systems, Minneapolis, MN; [8,5'-
3H]-guanosine 3,5'-cyclic monophosphate (specific activity 33.3 Ci/
mmol)from NewEnglandNuclear, Boston, MA; L-arginine, D-ar-
ginine, LPS (E. coli serotype 026:B6, phenol extracted), 3-isobutyl-
1-methyl-xanthine (IBMX),bovine liversuperoxide dismutase, bo-
vine red blood cell hemoglobin, methylene blue, sulfanilamide,
naphthylethylenediamine HCl, cGMP, andall otherreagents were
purchased from Sigma Chemical Co., St. Louis, MO.
Cell IsolationandCulture.
￿
Calfkidneyswere used to initiate bo-
vine glomerular mesangialcell cultures (GMC). GMCclones were
established as described(18) andused at passages 10 to 15. Individual
cell clones were characterized morphologically and by expression
of angiotensin II receptors as well as the absence of factor
VIII-related antigenexpression or uptake offluorescent acetylated
LDL. Cells were fed every 48 h with RPMI 1640 medium sup-
plemented with L-glutamine, 15% low endotoxin supplemented
bovine calf serum, 100 U/ml penicillin, 100 hg/ml streptomycin.
Bovine renal artery vascular smooth muscle cells (VSMC) were iso-
latedfrom therenalartery ofthe same calfusingpublishedmethods
(20). Individual cell clones of VSMC were established to obtain
pure cell populations then cultured under conditions identical to
GMC. Cellswere used at passages 5 to 8. COS-1 amonkey-derived
kidney cell line (ATCC CRL 1650) and 1502 (ATCC CRL 1502)
anormal humanskin fibroblast cell line were obtained from Amer-
ican Type Culture Collection, Rockville, MD.
cGMP Assay.
￿
Bovine GMC were plated on 12-mm glass cov-
erslips in 24-well plates. Replicate plated coverslips of GMC con-
tained 0.9-1.2 x 105 cells/coverslip as determined by Coulter
counter (Coulter Electronics, Hialeah, FL). GMC were kept in
serum-free medium for 48 h before assay. Cell monolayers were
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gently washed with 1 ml of a physiologic salt solution composed
of 130 mM NaCl, 5 mM KCI, 10 MM D-glucose, 1 MM MgC12,
1.5 mM CaC12, 25 mM Hepes (pH 7.4). Additions to the incu-
bation buffer had no effect on pH of the medium. Coverslips of
GMC were removed from 24-wellplates, placed in 12-well plates,
and allowed to equilibrate for I h at 37°C in 1 ml of incubation
buffer. IBMX (1 mM)wasadded 5 or 10 min, as indicated, before
termination of the assay. To terminate the assay, GMC coverslips
were placed into 0.5 ml ofice-cold 15% trichloroacetic acid. Samples
were then transferred to 12 x 75-mm glass tubes, extracted four
times with 2 ml ofwater-saturated ether, vacuum lyophilized, and
stored at -20°C fordeterminationofcGMP. GMCcell-associated
cGMP wasdetermined by radioimmunoassay.To determinetheeffect
ofrHuTNF-a and L-NMMA on other cell types, cells were grown
on 18-mm glass coverslips in 12-well tissue culture plates. To en-
sure that intracellular L-arginine levels were not rate-limiting, 100
pM L-arginine wasincluded in theassaybuffer. Fortheco-incubation
assay, GMC grownon 12-mmglasscoverslips were placed inverted,
by use of sterile technique, on 30-mm Millipore Millicell culture
inserts. Inserts were placed in 6-well culture plates with GMC,
treated with TNF-a or vehicle, or no cells. Cells were allowed to
equilibrate for 1 h at 37°C in 3 ml of incubation buffer and addi-
tions were made directly to theco-incubation assay. In this cocul-
ture system, cell monolayers are spatially separated but both are
exposed to added agents. The abilityto grow and treatmonolayers
individually, to bring them together only for the period of co-
incubation and separate the monolayers to determine reporter
GMC-associated cGMP levels allowed thedetermination ofwhether
TNT-a-treated donormonolayers released soluble mediators that
modulated cGMP production in reporter monolayers. To exclude
cGMP uptake from the extracellular medium we determined
whether GMC demonstrated specific uptake of [3H]cGMP. [3H]-
cGMP (1 pmol/ ml)was added5, 10, 20, or 60 minto GMC main-
tained for 1 h in incubation buffer at 37°C, in both the presence
and absence of 1 nmol/ml unlabeled cGMP. To terminate uptake,
GMC were rapidly washed four times with 1 ml volumes of ice-
cold 150 mM NaCl, 0.2% BSA (Fraction V). Cell-associated
[3H]cGMP, extracted as described above, was determined by scin-
tillation counting.
NitriteandNitrateAnalysis.
￿
Nitrite andnitratein tissue culture
medium were determined as described(21). Cells were treated for
48 hwith concentrations ofrHuTNF-a over theconcentration range
0.1-250 ng/ml in phenol red- and serum-free culture medium
(DMEM). After centrifugation at 3,000 g for 15 min, nitrate in
theculture supernatant wasreducedby usingnitratereductase (22).
Nitrite concentration of the resulting supernatant was taken to
reflect total nitrite/nitrate in the medium. To 150 pl of cell super-
natant, 900 pl of theGriess reagentwasadded. The Griess reagent
(final concentrations in thereaction mixture: 0.75% sulfanilamide
in 0.5 N HCl/0.075% N-(1-naphthylethylene diamine diHCl in
H2O) reacts with nitrite to form a chromophore absorbing at
543 nm, whichis quantitated spectrophotometrically. Usingknown
concentrations of NaN02, a standard curve can be constructed
over the linear range of the assay (0-50 p.M nitrite). Noncondi-
tioned medium had trace levels of nitrite measuring 0.40 ± 0.01
/AM (n = 3, duplicate determinations).
Data Analysis.
￿
Unless otherwise indicated, data are expressed
as the mean ± SE obtained in at least three separate experiments.
Comparisons were made with analysis of variance followed by Dun-
nett's modification of the t-test whenever comparisons were made
with acommon control andtheunpaired two-tailed Student'st test
for other comparisons. The level of statistically significant differ-
ence was defined as p < 0.05.
Tumor Necrosis Factor ot-treated Mesangial Cells Produce Nitric OxideResults
The Effect of Tumor Necrosis Factor on Mesangial Cell Cyclic
GMPContent. Addition of 100 ng/ml rHdTNF-a for 24 h
increased bovine mesangial cell-associated cGMP from base-
line values of 0.12 ± 0.01 to 0.41 t 0.01 pmol/106 cells
(n = 3, triplicatedeterminations, p < 0.01). Addition of the
phosphodiesterase inhibitor, IBMX (1 mM, 10 min), poten-
tiated the TNF-a-induced increase in GMC cGMP, with
values increasing from 0.32 ± 0.06 to 8.97 ± 1.05
pmol/106 cells (n = 3, triplicate determinations, p < 0.001).
Levels ofcGMP in medium conditioned for 24 h by vehicle-
treated GMC averaged 0.06 ± 0.01 pmol/ml. After 24 h
of TNF-a (100 ng/ml) cGMP levels in GMC-conditioned
medium were 0.15 ± 0.01 pmol/ml (n = 3) (p < 0.001).
Fig. 1 A demonstrates the time-dependent increase in GMC
cGMP after addition of 100 ng/ml rHuTNF-a. TNF-a-
induced increases in cGMP levels were evident at 8 h and
maximal at 18-24 h (n = 4, triplicate determinations). Shown
in Fig. 1B, rHuTNF-a produced a concentration-dependent
increase in the cGMP content of GMC treated for 24 h with
TNF-a doses ranging from 0.1 to 250 ng/ml (threshold 1.0
ng/ml, maximal response 100 ng/ml, n = 3, triplicate deter-
minations). Half-maximal responses were estimated from log-
logittransformation of the data and averaged 13.8 t 3.7 ng/ml
(n = 6, triplicatedeterminations). Though not shown, treat-
ment of GMC with doses of rHuTNF-a ranging from 0.1
to 100 ng/ml for 8 h led to a similar dose-dependent eleva-
tion in GMC cGMP content with half-maximal responses
seen at rHuTNF-a concentrations averaging 21.4 t 5.3 ng/ml
(n = 3, triplicate determinations).
The effects of several pharmacologic agents on basal and
TNF-a-stimulated GMC cGMP productionis shown in Fig.
2. GMC were treated for 10 min with the noted agents and
IBMX (1 mM) for 5 min before determination ofcGMP con-
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tent. Hemoglobin (oxygenated, 10 AM) markedly lowered
TNF-a-induced mesangial cell cGMP accumulation on av-
erage by 81.9 ± 4.9% (n = 3). Methylene blue (10 AM),
similarly lowered TNF-a-induced increases in mesangial cell
cGMP on average by 79.6 ± 3.7% (n = 3). Superoxide dis-
mutase (SOD, 100 U/ml) significantly increased TNF-a-
stimulated mesangial cell cGMP levels by an average 74.0 ±
22.2% (n - 3). Basal mesangial cell-associated cGMP levels
tended to be lower in the presence of hemoglobin or methy-
lene blue and higher in the presence of SOD, compared with
control cells. However, these changes failed to reach statistical
significance.
To determine whether de novo RNA or protein synthesis
was required for TNF-a-induced increases in mesangial cell-
associated cGMP, cellswere treated with actinomycin D (0.2
p.g/ml) or cycloheximide (0.2 Ag/ml) for 24 h in the pres-
ence and absence of rHuTNF-a (100 ng/ml). As shown in
Table 1, cycloheximide and actinomycin D abrogated TNF-
a-induced increases in bovine GMC cGMP levels.
TNF-induced Increases in Mesangial CellcGMP Are LArgi-
nine-dependent. t-NMMA decreased mesangial cell-associated
cGMP levels in TNF-a-treated, but not vehicle-treated GMC
in a concentration-dependent manner over the range from
1 to 2,500 AM (Fig. 3 A). Half-maximal responses were esti-
mated from log-logit transformation of the data and aver-
aged 53.0 ± 2.6 AM (n = 3, triplicate determinations). Max-
imal inhibition of TNF-a-induced increases in mesangial
cell-associated cGMP levels were observed at 2,500 AM and
averaged 84.3 ± 5.4% inhibition (Fig. 3 A). L-NMMA at
a concentration of 250 AM induced a response representing
on average 95.3% of the maximal L-NMMA-induced inhi-
bition. Shown in Fig. 3 B, addition ofL-arginine at concen-
trations ranging from 0.01 to 10 mM reversed the L-NMMA-
induced (250 AM) inhibition ofTNF-a-induced GMC cGMP
.1 1
Figure 1.
￿
Determination ofglomer-
ular mesangial cell-associated cGMP in
response to TNF-a. Cells were treated
with 1 mM IBMX 10 min before ex-
traction of cGMP. (A) Time course of
rHdrNF-0f_ (100 ng/ml) induced in-
creases in mesangial cell cGMP (B)
Concentration-response curve for
rHuTNF-a-induced increases in mesan-
gial cell cGMP content, measured at
24 h. Data points represent mean t SE,
1 0
￿
100
￿
n = 3-4, triplicate determinations.
Where error bars are not evident, SE
TNFa (n g /1111)
￿
was smaller than data point.Figure 2 .
￿
Effects of agents on mesangial cell cGMP content. Mesan-
gial cell-associatedcGMP levels 24h after addition ofvehicle (hatched ban)
or rHuTNF-a (100 ng/ml) (solid bars) . Cells were pretreated for 10 min
before assay termination with vehicle (control), hemoglobin (oxygenated,
10 uM), methylene blue (10 izM), or superoxide dismutase (100 U/ml) .
IBMX (1mM) was added 5 min before assay termination. Columns repre-
sent mean ± SE of three experiments, triplicate determinations . 'p < 0.05
vs. TNF-a-treated GMC .
accumulation in a concentration-dependent manner (n = 3) .
Half-maximal responses averaged 970 t 760 J.M L-arginine.
In the absence of L-NMMA, L-arginine (5 mM) had no
significant effect on cGMP levels in vehicle- or TNF-a-treated
GMC (100 ng/ml, 24 h) (n = 3, data not shown) . The
L-arginine effect was stereospecific in that D-arginine (5 mM)
did not reverse L-NMMA-induced inhibition and had no effect
on levels ofcGMP in vehicle- or TNF-a-treated GMC (n =
3, data not shown) .
cu
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Table 1 .
￿
Effect ofActinomycin D and Cycloheximide on
TNF-a-induced Increases in GMC cGMP Levels
Mesangial cGMP
Condition
￿
Control
￿
Actinomycin D
￿
Cycloheximide
pmol/106 cells
rHuTNF-a - 0.42 ± 0.05
￿
0.33 ± 0.01
￿
0.33 ± 0.02
rHuTNF-a* 3.15 t 0.43
￿
0.28 ± 0.01"
￿
0.43 ± 0.05'
Effect of 24-h treatment with actinomycin D (0 .2 tag/ml) or cyclohexi-
mide (0.2 Ag/ml) on cycliccGMP content of mesangial cells treated with
vehicle or rHuTNF-a (100 ng/ml) for 24 h . Cells were treated with
1 mMIBMX 10 min before extraction ofcGMP . Data points represent
mean t SE, n = 3, triplicate determinations .
p < 0.01 vs . TNF-a-treated cGMP levels .
Effects ofLPS, IM0, IFN-y, and TGF-ß 1 on GMC GMP
Levels. It was ofinterest to determine whether the addition
of microbial products or cytokines other than rHuTNF-a
could modulate levels ofGMC cGMP. Shown in Fig. 4 are
the effects ofrHuTNF-a (25 ng/ml), rHuILlß (25 ng/ml),
LPS (1 jug/ml), and rHuIFN-y (200 U/ml) on mesangial
cell-associatedcGMP as a function oftime (n = 3, triplicate
determinations) . As shown, rHuIFN-y had no affect onGMC
cGMP levels . In separate studies, purified human IFN-y also
failed to modulate GMP cGMP content (data not shown) .
Addition of rHuILlß or LPS for 8 h increased mesangial
cell-associated cGMP levels. Of interest, rHuILlß- and
rHuTNF-ot-induced increases in mesangial cell cGMP that
were significantly greater than those observed after treatment
ofGMC with LPS (p < 0.05) .
Figure 3 .
￿
Effect of L-NMMA and
L-arginineon TNF-a-induced increases
in mesangial cell cGMP. Cells were
treated for 24 h with 100 ng/ml
rHuTNF-a . The cGMP content of
mesangial cells treatedfor 24 hwith ve-
hicle averaged 0.33 t 0.09 pmol/106
MRS . L-NMMA, L-arginine, andIBMX
(1 mM) were added 10, 7.5, and 5 min
before termination ofthe assay, respec-
tively. (A) Concentration-response re-
lationship for L-NMMA-induced
decreases in the cGMP content of
rHuTNF-a-treatedmesangial cells. (B)
Concentration-response relationship
for L-arginine-stimulated reversal of
L-NMMA,-induced(250 AM) inhibition
ofmesangial cellcGMP content . In the
absence ofL-NMMA cGMP levels in
TNF-a-treated mesangiai cells averaged
2.91 t 0.50 pmol/106 cells . Data
points represent mean ± SE, n = 3,
triplicate determinations. Where error
bars are not evident, SEwas smaller than
L-ARG IN I NE (~M)
￿
data point.
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￿
Effect of rHuIFN~y (200 U/ml), LPS (1 14g/ml), rHuTNF-a
(25 ng/ml), and rHuIITIO (25 ng/ml) on mesangial cell cGMP content
as a function of time. Cells were treated with 1 mMIBMX 10 min before
extraction ofcGMP . Data points represent mean ± SE, n - 3, triplicate
determinations . Where error bars are not evident, SE was smaller than
data point . (O) IFN -'y, (/) LPS, (") TNF-a, (O) 1140 .
We further determined the effect of treatment for 24 h
with rHuIFN- ,y, LPS, and rHuIIr1fl in the absence or pres-
ence ofrHuTNF-a . TNF-a was added at threshold (1 ng/ml)
and maximal doses (100 ng/ml) . IFN-T (200 U/ml) had no
significant effect on mesangial cell-associated cGMP levels
in either the presence or absence ofTNF-a (data not shown) .
As was seen at 8 h, treatment ofGMC with LPS (1 14g/ml)
for 24 h increasedGMC cGMP levels (0.40 ± 0.05 and 0.90
± 0.12 pmol/106 cells for control and LPS-treated GMC,
respectively, n = 3, p < 0.05) . Furthermore, LPS potentiated
in a synergistic fashion the effect of a threshold dose ofTNF-a
(0.84 ± 0.10 and 2.77 ± 0.46 pmol/106 cells for GMC
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treated with TNF-a or TNF-a and LPS, respectively, n =
3,p < 0.05) . In contrast, LPS did not significantly increase
levels ofcGMP in GMC treated concurrently with a max-
imal dose ofTNFLot (data not shown,n = 3).11,10 (25 ng/ml)
increased mesangial cell-associated cGMP levels at 24 h to
values that were not significantly different from the effect
ofa maximal dose ofTNF-a . Moreover, M1a increased levels
ofcGMP inGMC treated with threshold or maximal doses
ofrHuTNF-a in a manner that was additivewhen compared
with the observed effect ofGMC treated withTNF-a alone
(n = 3) . For example, levels ofcGMP in controlGMC aver-
aged 0.40 ± 0.05 pmol/106 cells, whereas cGMP levels in
TNF-a- (100 ng/ml), 11,10- (25 ng/ml), and TNF-a/11,
1/3-treated GMC were 6.75 ± 0.42, 6.34 ± 0.65, and 14.21
± 1.72 pmol/106 cells, respectively . TGF-at (10 ng/ml,
24 h) had no significant effect on GMC cGMP levels (0.36
± 0.05 vs . 0.37 ± 0.05 pmol/106 cells, for vehicle- and
TGF-at-treated cells, n = 3) . However, levels ofcGMP in
GMC treated concurrently with TNF-a (100 ng/ml, 24 h)
and TGF-/3 t (10 ng/ml, 24 h) were lower than cGMP levels
in TNF-a- (100 ng/ml, 24 h) treated GMC (3.16 ± 0.21
vs . 7.15 ± 0.20 pmol/106 cell, n = 3, p < 0.01) .
Effect of TNF on Cyclic GMP Production by Various Cell
Types. Given that rHuTNF-a increased GMP levels inGMC
via an L-arginine-dependent mechanism, it was of interest
to determine whether TNF-a had a similar effect on other
cell types . Fig. 5 demonstrates the effect ofTNF-a treatment
(100 ng/ml, 24 h) on levels ofcGMP in bovine renal artery
VSMC, a human skin fibroblast cell line (1502) and COS
1 cells . To ensure that intracellular L-arginine levels were not
rate-limiting, 100 JIM L-arginine was included in the assay
buffer. TNF-a treatment for 24 h increased levels ofintracel-
lular cGMP in the three cell types studied (5 min, 1 mm
IBMX, n = 3, triplicate determinations) . Compared with
the large increase in cell-associatedcGMP observed inGMC
after addition of 100 ng/mlrHuTNF-a for 24 h, an average
8.23 ± 1.07-fold increase (5 min, 1mMIBMX), TNF-a-in-
duced increases in VSMC, fibroblasts, and COS 1 cGMP levels
Figure 5 .
￿
Effect of 24-h treatment
withvehicle (contron or rHuTNF-a (100
ng/ml) on cell-associated cGMP levels
in bovine renal artery VSMC, human
skin fibroblast (1502) cells, and renal-
derived COS 1 cells. To ensure that in-
tracellular L-arginine levels were not
rate-limiting 100AML-arginine was in-
cluded in the assay buffer. L-NMMA
(500 AM) and IBMX (1 mM) were
added 10and 5 min before termination
of the assay, respectively. Columns rep-
resent mean t SE, n - 3, triplicate
determinations. `p < 0.05 vs . control
GMC, "p < 0.05 vs . TNF-a-treated
GMC .were 2.79 ± 0.05, 1.76 t 0.28- and2.28 ± 0.30-fold above
baseline values, respectively. Thefold increase in GMC cGMP
content in response to TNF-ac treatment was significantly
greater than theincrease observed with these othercell types
(each case p < 0.05 vs. TNF-a-treated GMC). L-NMMA
(500 p,M, 10 min) decreasedlevels ofcGMP in TNF-a-treated
VSMC, skin fibroblasts, andCOS 1 cells. WhereasL-NMMA
failed to decrease levels of cGMP in vehicle-treated VSMC
or GMC, as also shown earlier, L-NMMA decreased levels
of cGMP in vehicle-treated fibroblasts and COS 1 cells.
GMC Treated with TNFReleasea Soluble Factor that Increases
cGMP in Adjacent Cells. The finding of TNF-a-stimulated
L-arginine-dependent cGMP production by GMC suggested
that TNF-ainducestheproduction of NO by GMC. It was
thereforeofinterest to determine whetherdonormonolayers
of TNF-a-treated GMC released a factor(s) that could aug-
ment cGMP production in reporter monolayers. Untreated
GMC, serving as reporter monolayers, were grown on cov-
erslips and placed inverted in the upper chamber of Millicell
culture inserts. Inserts were then placed in wells that con-
tained confluent donormonolayers of GMC: vehicle- or TNF-
a-treated. Levels of cGMP in thesereporter monolayers were
greater in the presence of TNF-a-treated GMC than in the
presence of vehicle-treated GMC, but only in the presence
of SOD (200 U/ml) (Table 2) . Levels of cGMP in GMC
reporter monolayers placed on controlGMCdonormonolayers
were not different than cGMP levels in GMC reporter
monolayers studied in the absence of a donor cell type. It
is unlikely that uptake of extracellular cGMP, released from
donor monolayers, mediated theobserved increase in reporter
monolayer cGMP content. GMCuptake of [3H]cGMP aver-
aged 0.7 ± 0.1, 1.4 ± 0.2, 2.5 ± 0.3,and6.7 ± 0.3%
of added counts at 5, 10, 20, and 60 min, respectively (n =
Table 2.
￿
Effect of Donor Monolayers on Cyclic GMP Content
of Responder Cell Monolayer
Donor cell
Responder cell cGMP
Control
￿
Superoxide dismutase
Effect of donormonlayers on cGMP content ofresponder cell monolayer.
Confluent monolayers of responder cells, glomerular mesangial cells,
GMC, grown on glass coverslips, were placed inverted in 30-mm Mil-
licell cultureinserts on confluent donor monolayers. Donormonolayers:
none, vehicle-treated GMC, rHuTNF-a-treated (100 ng/ml, 24 h) GMC
were grown on 6-well plates. The co-incubation assay was treated with
IBMX (1 mM, 10 min) and whereindicated superoxide dismutase (200
U/ml, 10 min). Cell-associated cGMP levels were determined in responder
monolayers. Data points represent mean ± SE, n = 4, duplicate deter-
minations.
p < 0.01 vs . control GMC cGMP levels.
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3, triplicate determinations). Assuming that incorporated
tracer was not metabolized, levels of GMC [3H]cGMP at 60
min would correspond to 0.03 pmol cGMP/106 cells. Given
that levels of cGMP in the medium of GMC were -0.1
pmol/ml andthat uptake from medium containing 1pmol/ml
[3H]cGMP accounted for <10% of cell-associated cGMP, it
is unlikely that uptake of cGMP accounts for the increased
levels of cGMP in reporter monolayers incubatedwith TNF-
a-treated donor monolayers. GMC uptake of [3H]cGMP
was competitively inhibited by unlabeled cGMP, with up-
take at 60 min averaging 1,672 ± 76 cpm/106 cells and 521
± 30 cpm/106 cells in the absence and presence of 1 nmol/
ml unlabeled cGMP, respectively (n = 3, triplicate determi-
nations, p < 0.05). Moreover, uptake was significantly lower
at 4°C andnot modified by treatment ofGMC with TNF-a
for 1 or 24 h (data not shown). Interestingly, IBMX (1 mM,
1 h) significantly inhibiteduptake of extracellular [3H]cGMP
(1,419 ± 50 vs. 165 ± 5 cpm/106 cells measured at 60 min,
p < 0.01). Therefore, though GMC uptake of [3H]cGMP is
inhibited by unlabeled cGMP, temperature-sensitive and
blockedby IBMX, themagnitudeofthis uptake is insufficient
to account for the results ofthe coincubation assay. The ob-
servation that cGMP levels are increased in GMC cocultured
with TNF-treated donor GMC monolayers, but only in the
presence of SOD, is consistent with thehypothesis that TNF-
treated GMC release NO.
TNF Increases Nitrite/Nitrate in the Medium ofGlomerular
Mesangial Cells. Fig. 6 demonstrates TNF-a-induced in-
creases in the content of nitrite/nitrate (N02 -/NO3 -) in
themedium of GMC. Measured at 48 h, rHuTNF-a at con-
centrations ranging from 0.1 to 250 ng/ml increased the
N02_/NO3_ content of the culture medium in a dose-
dependent manner (n = 4, duplicate determination).
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Figure 6.
￿
Determination of theN02-/N03- content in the medium
of mesangial cells treated with increasing concentrations of rHuTNF-a
for48 h. Data points representmean t SE, n = 3, duplicatedeterminations.
Tumor Necrosis Factor a-treated Mesangial Cells Produce Nitric Oxide
None
pmol/106
0.31 ± 0.03
cells
0.34 ± 0.03
E
c
Vehicle-treated GMC 0.30 ± 0.01 0.30 ± 0.01 M
rHuTNFce-treated GMC 0.29 ± 0.01 0.77 ± 0.04" O
ZDiscussion
Biosynthesis of NO represents a complex enzymatic pro-
cess that converts guanido nitrogens of L-arginine to NO via
an NADPH-dependent citrulline-forming enzyme (23, 24).
NO synthase activity is constitutivelyexpressed in endothelial
cells (25), neutrophils (26), the adrenal gland (27), and cere-
bellar cells (28, 29) though basal ratesof EDNO release can
be augmented by agonists that increase cytosolic calcium con-
centration. In macrophages, NO generation is induced by
IFN-y alone or in combination with bacterial LPS or muramyl
dipeptides, the combination ofIFN-'y with TNF-a or TNF-0,
and IFN-a or IFN-)3 with LPS (21, 30-32). The enzyme
activity in macrophages is cytosolic and dependent upon the
cofactors NADPH, reduced biopterin (33), and FAD flavo-
protein (34). But unlike the constitutive enzyme of endothelial
cells, macrophageenzyme activity does not appear to be de-
pendent on calcium. Evidence now indicates that NO syn-
thesis can also be induced in some tumor cells (35, 36) and
Kupffer cells (37). Given that NO generation may be widely
expressed it was of interest to determine whether GMC can
be induced to produce NO and whether mesangial-derived
NO modulates GMC function.
TNF-a increased mesangial-associated cGMP content in
a time- and concentration-dependent manner. Increases in
GMC cGMP content were evident as early as 8 h and max-
imal at 18- 24 h (Fig. 1). TNF-a-induced increases in mesan-
gial cGMP levels were observed in both the presence and ab-
sence o£ IBMX, an inhibitor of phosphodiesterase activity,
suggesting enhanced production of cGMP as opposed to in-
hibition of cGMP degradation. Levels of cGMP were higher
in the medium of GMC treated for 24 h with TNF-a com-
pared with vehicle-treated GMC. We attribute the small in-
crease in medium cGMP to the high capacity ofcell-associated
5'-nucleotidase activity.
The pharmacologic manipulations used provide evidence
that the active agent released by TNF-a-activated GMC was
related to NO. TNF-a-induced mesangial cell cGMP accumu-
lation was inhibited by methylene blue and hemoglobin and
potentiated by superoxidedismutase (SOD) (Fig. 2). Methy-
lene blue mediates its effects through inhibition of soluble
guanylate cyclase, thereby inhibiting NO action on the target
enzyme. EDNO action is also potently inhibited by hemo-
globin. NO binds to this and other heme-containing pro-
teins, including soluble guanylate cyclase, forming nitrosyl-
heme adducts (38). Hemoglobin, a molecule whose size
precludes access to the intracellular compartment, inhibited
TNF-a-stimulated increases in GMC cGMP content, indi-
cating that the mediator(s) implicated in the activation of
mesangial cell guanylate cyclase had free access to the extracel-
lular compartment. SOD catalyzes the reaction 202- +
2H+ - 02 + H202. The pharmacologic half-life of NO
is markedly shortened in the presence of superoxide radical
(02 -), a mechanism possibly involving the production of
nitrogen oxides from NO. Although cGMP levels in vehicle-
treated GMC tended to be lower in the presence of hemo-
globin or methylene blue and higher in the presence of SOD
these changes failed to reach statistical significance. The finding
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in the current study that TNF-a-induced elevations of mesan-
gial cell cGMP content were blunted by hemoglobin and
methylene blue and potentiated by SOD is consistent with
the view that TNF-a-activation ofGMC soluble guanylate
cyclase is mediated by NO.
NO is synthesized from the semi-essential amino acid
L-arginine. L-NMMA serves as an enantiomerically specific
competitive inhibitor of NO synthesis. L-NMMA is an in-
hibitor of macrophage cytotoxicity and N02 - or N03-
production (16, 21). Systemic infusion ofL-NMMA induces
a potent pressor response and local infusion of L-NMMA in-
creases vascular resistance (39-41). Both ofthese L-NMMA-in-
duced effects can be reversed with L- but not n-arginine. In
isolated vascular smooth muscle rings, L-NMMA induces a
small but significant endothelium-dependent vasoconstriction
and blunts the vasodilatory response to acetylcholine (42).
These observations have been taken to suggest that L-NMMA
inhibits basal release of EDNO in vivo and in vitro. Activity
of NO synthase in endothelial, macrophage, cerebellar, and
adrenal homogenates is inhibited by L-NMMA in a concen-
tration-dependent manner (27, 29, 33, 43). The L-arginine
dependence of NO synthesis in other cell types suggested
that TNF-a-induced increases in GMC cGMP content may
be L-arginine dependent. In the current study we have demon-
strated that TNF-a-induced elevations ofGMC cGMP con-
tent are dependent upon L-arginine in that L-NMMA decreased
cGMP levels in a TNF-a-treated GMC in a concentration-
dependent manner (Fig. 3). L-NMMA-induced inhibition
could be reversed by L-arginine in a competitive manner. Com-
petitive reversal by L-arginine was enantiomerically specific
because n-arginine was without effect . It was of interest that
L-arginine had no effect on rates ofcGMP production by TNF-
a-treated GMC, suggesting that enzyme activity was not
limited by the cellular content of free L-arginine, even when
GMC had been maintainedfor 1 h in a physiologic salt solu-
tion devoid of L-arginine. Furthermore, L-NMMA had no
effect on cGMP levels of vehicle-treated GMC, suggesting
that basal rates of mesangial cGMP production were not de-
pendent upon L-arginine. Consistent with the hypothesis that
TNF-a induces the formation ofNO in GMC is the demon-
stration of nitrogen oxides (N02- and N03-) in the con-
ditioned medium of TNF-a-treated GMC (Fig. 6).
The most reasonable interpretation of our observations is
that TNF-a induces in GMC the expression of an enzyme(s)
involved in the formation of L-arginine-derived NO. Our
findings that inhibitors of new RNA synthesis or protein
synthesis abrogate TNF-a-induced increases in GMC cGMP
content are taken to represent an effect of TNF-a on tran-
scription of a gene whose protein product is rate-limiting
for L-arginine-dependent NO synthesis, possibly NO syn-
thase. Expression of enzyme activity is minimal in vehicle-
treated GMC in that cGMP production was not blunted by
L-NMMA though cells could respond to sodium nitroprus-
side, an exogenous activator ofmesangial cell soluble guany-
late cyclase, with elevation ofcGMP content (datanot shown).
Macrophages in culture treated with IFN--y and LPS syn-thesize nitrogen oxides (NO, N02- , and N03-) and L-cit-
rulline from L-arginine (17, 33, 44). This enzymatic activity
is dependent upon activation of macrophages, given that it
is absent from unstimulated cells. Furthermore, induction of
enzymatic activity requires new RNA and protein synthesis.
In many regards, therefore, TNT-a-treated GMC resemble
activated macrophages. However, the present study suggests
that macrophages and mesangial cells differ with respect to
the cytokines capable of activating the NO synthetic activity.
We found that TNF-a induced NO production by mesan-
gial cells, whereas previous studies showed that TNF-ac had
minimal effect on nitrogen oxide(s) production by macro-
phages, although TNF-a augmented IFN-y-induced nitrogen
oxide(s) production (31, 32). Furthermore, whereas IFN-y
apparently augmented NO production by macrophages, in
this study rHuIFN-y was without effect in unstimulated and
in TNF-a-stimulated mesangial cells. IFN-y induces the ex-
pression of MHC class I and class II antigens in rat GMC
(45), indicating a functional response in this cell type. How-
ever, the possibility that bovine GMC fail to respond to
rHuIFN-y cannot be excluded. Responses by macrophages
and GMC to ID10 also appear to differ. RAO does not have
a significant effect on macrophage nitrogen oxide produc-
tion and does not act as a cofactor when added in the pres-
ence of IFN-y (32, 46). By contrast, ID10 increased mesan-
gial cell-associated cGMP levels at 24 h to values that were
not significantly different from the effect ofmaximal TNF-a
doses, and addition of IWO to GMC treated with maximal
doses of TNF-a increased cGMP levels above cGMP levels
achieved with TNF-ca alone. Increases in the cGMP content
of 11,10-treated GMC are of interest in that IL1o treatment
ofvascular smooth muscle strips impairs contractile responses
in an endothelium-independent manner (47). Recent obser-
vations suggest that 11,1 activates guanylate cyclase in rat vas-
cular smooth muscle rings and cultured VSMC, an effect that
is blocked by hemoglobin and methylene blue (48).
LPS toxicity is thought to be mediated in large part by
TNF-at, and LPS stimulates TNF-a production by macro-
phages and by rat mesangial cells (49). Therefore, it was of
interest that LPS could also induce NO-dependent cGMP
productionby mesangial cells. Prolonged exposure ofrat aorta
to low levels of endotoxin in vitro results in impaired con-
tractility that may be mediated by cytokines derived from
the vasculature (50) and preliminary observations suggest that
this effect that can be reversed with L-NMMA (51). Thus,
this study demonstrates that TNF-a, IWO, and LPS increase
cGMP levels in GMC. Furthermore, cytokine-induced re-
sponses of GMC differ from those reported for macrophages.
Whether the apparent differences result from differences in
the cytokine receptors expressed on the two cell types remains
to be determined. It is of interest that TGF-(3 blocked the
ability of IFN-y to induce release of nitrogen oxides from
mouse peritoneal macrophages (52). We have also demon-
strated that TGF-/31, though not modulating GMC cGMP
levels by itself, blunted the TNF-a response.
To extend our observations we determined the effect of
TNF-a on the cGMP content of bovine renal artery VSMC,
a human skin fibroblastcell line (1502) and renal-derived COS
1 cells. In each of the cell types examined, TNF-a increased
cGMP production and L-NMMA decreased cGMP levels in
TNF-a-treated cells, suggesting that cell types other than
GMC respond to TNF-a with induction of NO synthase
activity. In contrast to the lack of effect ofL-NMMA on basal
GMC or renal artery VSMC cGMP production, L-NMMA
decreased basal levels of cGMP in 1502 fibroblasts and COS
1 cells. We interpret these observations to suggest that basal
rates of guanylate cyclase activity in COS 1 cells and 1502
fibroblasts are L-arginine dependent.
Current evidence suggests that NO synthesized by donor
cell types, such as endothelial cells, can stimulate soluble guany-
late cyclase in adjacent responder cell types, such as VSMC
or GMC (15, 24). For instance, within the renal glomerulus,
glomerular endothelial cells (GEN) can serve as a source of
EDNO, to which GMC can respond (18). We therefore de-
termined whether TNF-a-treated GMC release a factor to
which adjacent cells can respond. Levels ofcGMP were higher
in reporter GMC monolayers cocultured in Millicell culture
systems with TNF-a-treated GMC compared to vehicle-
treated GMC, but only in the presence of SOD. Though the
uptake of extracellular cGMP is unlikely to account for this
observation in that GMC exhibit a low capacity uptake pro-
cess for cGMP, we cannot exclude a minor contribution of
extracellular cGMP. The low capacity for cellular uptake of
cGMP is consistent with the weak biologic effects of cGMP
on intact tissue where lipidsoluble analogues, namely 8'-bromo-
cGMP and dibutryl-cGMP, are more effective. Furthermore,
the observed requirement for SOD in the coculture experi-
ments suggests that the biologic activity ofNO was required
for this response. These data indicate that TNF-a-treated
GMC exert a paracrine effect on the cGMP content of adja-
cent cells. Our model suggesting a role for mesangial-de-
rived NO in the autocrine and paracrine modulation of cell
function, in this case activation of soluble guanylate cyclase,
would be similar to the proposed role for NO in activated
macrophages wherein NO has been suggested as the medi-
ator ofL-arginine-dependent autocrine and paracrine inhibi-
tion of cellular metabolism (17, 21, 44).
The results of the current study suggest that TNF-a in-
duces the expression in GMC of an enzyme(s) involved in
the formation ofL-arginine derived NO. Moreover, NO acts
in an autocrine and paracrine fashion to activate GMC soluble
guanylate cyclase. Since elevations in cGMP inhibit mesan-
gial cell contraction (19), the study suggests that NO pro-
duced by TNF-a-activated GMC may regulate mesangial cell
contractility in vivo under pathophysiologic conditions. Fur-
thermore, the data suggest that TNF-a induces the expres-
sion of NO synthase in vascular smooth muscle cells and
fibroblasts. As a possible mechanism for TNF-a-induced
hemodynamic changes we propose that TNF-ac increases NO
synthase activity within vascular tissues which, under basal
conditions, is otherwise poorly expressed. Consistent with
this hypothesis, Kilbourn et al. demonstrated that L-NMMA
inhibited TNF-induced hypotension (53). Recently, Beasley
et al. in this laboratory (48), also suggested that IIA-induced
hypotension could be mediated, in part, by the production
ofNO in vascular smooth muscle cells. This study suggests
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Tumor Necrosis Factor a-treated Mesangial Cells Produce Nitric Oxidethat NO producedby TNF-a-stimulated mesangial cells may
have an autocrine and paracrine action within the renal
glomerulas and in the postglomerular circulation, namely
stimulation of soluble guanylate cyclase, yet the renal response
to LPS or TNF-ci is intense vasoconstriction and reduction
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